Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1111101

	registered interest
	date	10/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent estimate his Department has made of the number of NHS prescriptions for medicine in which THC is the dominant ingredient.
	tabling member constituency	Newcastle-under-Lyme
	tabling member printed	Paul Farrelly
	uin	243361
	answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>The Department has made no estimate of the number of National Health Service prescriptions for cannabis-based products in which delta-9-tetrahydrocannabinol (THC) is the dominant ingredient.</p><p> </p><p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the NHS and independent sector.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 11:49:19 answering member 4455 label Biography information for Seema Kennedy previous answer version 114110 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1436 label Biography information for Paul Farrelly

1128442

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257706
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del class="ministerial">This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</del></p><p><del class="ministerial">In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:18:03 question first ministerially corrected 11/06/2019 11:31:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 121340 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1002107

	registered interest
	date	05/11/2018
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, whether his Department remains the ministerial lead for the medicinal use of cannabis-based products.
	tabling member constituency	Inverclyde
	tabling member printed	Ronnie Cowan
	uin	188186
	answer	answer is ministerial correction date of answer 15/11/2018 answer text <p>The Home Office leads the Government’s policy and legislation on the misuse of drugs, including on the scheduling of substances controlled under the Misuse of Drugs Act 1971 and associated legislation. The Department of Health and Social Care has responsibility for the safe management and use of medicines in healthcare.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 15/11/2018 17:58:05 answering member 1561 label Biography information for Mr Nick Hurd
	tabling member	4465 label Biography information for Ronnie Cowan

1002678

	registered interest
	date	06/11/2018
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, if he will publish the advice used to inform his Department on the requirements that (a) the decision to prescribe medicinal cannabis products must be made by a specialist doctor and (b) medicinal cannabis products may only be prescribed when the patient has an unmet special clinical need that cannot be met by other treatments.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	188750
	answer	answer is ministerial correction date of answer 12/11/2018 answer text <p>The prescription of these products by doctors on the Specialist Register of the General Medical Council (GMC) and only where there is an unmet clinical need follows the principles used by the Interim Expert Panel on cannabis-based products for medicinal use. This approach was agreed by senior clinicians on the Expert Panel, Chaired by Dr Michael McBride, Chief Medical Officer for Northern Ireland. This approach was subsequently supported by the Advisory Council on the Misuse of Drugs (ACMD) in their advice to the Home Secretary on rescheduling cannabis. The ACMD advice has been published and is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products" target="_blank">https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products</a></p><p>Any unlicensed medicines, including cannabis-based products for medicinal use, will be supplied under long-standing arrangements for the supply of what are known, in healthcare settings, as ‘specials’. This process is underpinned by the Human Medicines Act and, outside of clinical trials, only allows these unlicensed medicines to be prescribed where there is an unmet clinical need. This restriction is in place because unlicensed medicines have not been through the same quality, safety and efficacy tests as licenced medicines.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 12/11/2018 17:05:51 answering member 1561 label Biography information for Mr Nick Hurd
	tabling member	1439 label Biography information for Norman Lamb

1003743

	registered interest
	date	09/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to increase the (a) knowledge and (b) awareness among GPs of the benefits of medicinal cannabis.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	189815
	answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>The Government has rescheduled cannabis-based products for medicinal use from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. Doctors on the specialist register of the General Medical Council may now prescribe these products where there might be potential benefit to individual patients. General practitioners will not be able to prescribe but the Government has commissioned the National Institute for Health and Care Excellence to produce guidance for all clinicians by October 2019.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/11/2018 11:38:40 answering member 4067 label Biography information for Steve Brine
	tabling member	4623 label Biography information for Tonia Antoniazzi

1005764

	registered interest
	date	12/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NHS and medical professional body guidelines on the prescription of medicinal cannabis in ensuring the eligibility for prescription of patients for whom that treatment might be advantageous.
	tabling member constituency	Birkenhead
	tabling member printed	Frank Field
	uin	190361
	answer	answer is ministerial correction date of answer 15/11/2018 answer text <p>The Medical Director of NHS England, Professor Steve Powis, and the Chief Medical Officer, Professor Dame Sally Davies, have written to relevant clinicians to coincide with the coming into force of the rescheduling of cannabis-based medicinal products. The guidance in this letter, which signposts interim clinical advice commissioned from the British Paediatric Neurology Association and the Royal College of Physicians, is in line with normal clinical practice. The decision to prescribe cannabis-based products for medicinal use will be made on a case-by-case basis, based on clinical need and in-line with existing governance procedures for prescribing unlicensed medicines.</p><p> </p><p>The Department has commissioned the National Institute for Health and Care Excellence to produce clinical guidance by October 2019, which will update and replace the interim advice.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/11/2018 12:47:21 answering member 4067 label Biography information for Steve Brine
	tabling member	478 label Biography information for Lord Field of Birkenhead

1037068

	registered interest
	date	07/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of patients who have been (a) prescribed medicinal cannabis through the NHS and (b) denied a prescription for medicinal cannabis through the NHS since its use was legalised in November 2018.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	205815
	answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.</p><p> </p><p>The Department does not hold information on the number of patients denied access to prescriptions for medicinal cannabis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:08:42 answering member 4067 label Biography information for Steve Brine
	tabling member	308 label Biography information for Mr Jim Cunningham

1037890

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many NHS prescriptions have been issued for patients to use medical cannabis since 1 November 2018.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	206441
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.</p><p> </p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206442 206443 question first answered 16/01/2019 15:13:41 answering member 4067 label Biography information for Steve Brine
	tabling member	4623 label Biography information for Tonia Antoniazzi

1037900

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many NHS prescriptions for medicinal cannabis have been dispensed at a pharmacy since 1 November 2018.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	206442
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.</p><p> </p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206441 206443 question first answered 16/01/2019 15:13:41 answering member 4067 label Biography information for Steve Brine
	tabling member	4623 label Biography information for Tonia Antoniazzi

1037901

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of (a) prescriptions of and (b) patients who will use medical cannabis in the next 12 months.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	206443
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.</p><p> </p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206441 206442 question first answered 16/01/2019 15:13:41 answering member 4067 label Biography information for Steve Brine
	tabling member	4623 label Biography information for Tonia Antoniazzi